{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T23:12:08Z","timestamp":1761174728345,"version":"build-2065373602"},"reference-count":10,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2003,8,1]],"date-time":"2003-08-01T00:00:00Z","timestamp":1059696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,12,1]],"date-time":"2014-12-01T00:00:00Z","timestamp":1417392000000},"content-version":"vor","delay-in-days":4140,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2003,8]]},"DOI":"10.1046\/j.1469-0691.2003.00645.x","type":"journal-article","created":{"date-parts":[[2003,8,26]],"date-time":"2003-08-26T04:42:38Z","timestamp":1061872958000},"page":"893-896","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae"],"prefix":"10.1016","volume":"9","author":[{"given":"L.M.","family":"Deshpande","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. H","family":"Mutnick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.N.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 2","key":"10.1046\/j.1469-0691.2003.00645.x_bib1","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1086\/320181","article-title":"Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997\u20131999","volume":"32","author":"Hoban","year":"2001","journal-title":"Clin Infect Dis"},{"issue":"suppl","key":"10.1046\/j.1469-0691.2003.00645.x_bib2","first-page":"S8","article-title":"Old and new cephalosporins. Clinical utility and benefits","volume":"8","author":"Nightingale","year":"2001","journal-title":"J Respir Dis"},{"key":"10.1046\/j.1469-0691.2003.00645.x_bib3","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1128\/AAC.44.12.3272-3277.2000","article-title":"In vitro and in vivo activities of LB10827, a new oral cephalosporin, against respiratory pathogens","volume":"44","author":"Paek","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"year":"2000","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically. Approved standard M7-A5","author":"National Committee for Clinical Laboratory Standards","key":"10.1046\/j.1469-0691.2003.00645.x_bib4"},{"year":"2002","series-title":"Performance standards for antimicrobial susceptibility testing, 12th informational supplement","author":"National Committee for Clinical Laboratory Standards","key":"10.1046\/j.1469-0691.2003.00645.x_bib5"},{"key":"10.1046\/j.1469-0691.2003.00645.x_bib6","series-title":"Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA","first-page":"298","article-title":"Synthesis and antibacterial activities of LB10827, a new oral cephalosporin antibiotic [abstract 397]","author":"Oh","year":"1999"},{"key":"10.1046\/j.1469-0691.2003.00645.x_bib7","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/BF01645369","article-title":"Antibacterial activity of cefpodoxime in comparison with cefixime, cefdinir, cefetamet, ceftibuten, loracarbef, cefprozil, BAY3522, cefuroxime, cefaclor and cefadroxil","volume":"19","author":"Bauernfeind","year":"1991","journal-title":"Infection"},{"key":"10.1046\/j.1469-0691.2003.00645.x_bib8","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/0732-8893(91)90069-R","article-title":"In vitro activity evaluations of cefdinir (FK482, CI-983, PD134393): a novel orally administered cephalosporin","volume":"14","author":"Briggs","year":"1991","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2003.00645.x_bib9","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/0732-8893(92)90105-3","article-title":"Cefdinir, a new orally administered cephalosporin: in vitro activity comparison against recent clinical isolates from five medical centers","volume":"15","author":"Gerlach","year":"1992","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1046\/j.1469-0691.2003.00645.x_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0732-8893(01)00274-7","article-title":"Cefditoren in vitro activity and spectrum: a review of international studies using reference methods","volume":"41","author":"Jones","year":"2001","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14640854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14640854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:19:23Z","timestamp":1761117563000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14640854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,8]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2003,8]]}},"alternative-id":["S1198743X14640854"],"URL":"https:\/\/doi.org\/10.1046\/j.1469-0691.2003.00645.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"type":"print","value":"1198-743X"}],"subject":[],"published":{"date-parts":[[2003,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antimicrobial activity of LB10827, a new orally administered cephalosporin, tested against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1046\/j.1469-0691.2003.00645.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2003 European Society of Clinical Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}